Yuhua Li

Dr. Yuhua Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YLYuhua Li
Yuhua Li
TTTianle Tang
Tianle Tang
YSYang Sun
Yang Sun
GCGui’e Chen
Gui’e Chen
XYXinrong Yuan
Xinrong Yuan
DCDe Cai
De Cai
Chemotherapy, which aims to eradicate tumor cells and enhance patient survival, is a prevalent approach for tumor treatment. Nevertheless, recurrence and drug resistance resulting from consecutive chemotherapy regimens have emerged as significant factors contributing to the high fatality rates among cancer patients. Numerous studies have revealed that chemicals discharged by injured and deceased cells can trigger the host repair program mediated by toll-like receptor-4 (TLR-4), enhancing tumor resistance. TLR-4 is not only expressed in immune cells but also in various malignant tumor cells, especially inflammation-associated tumor cells, and plays a crucial role in tumor formation, development, and chemoresistance. Endogenous ligands are released upon the killing of tumor cells by chemotherapy drugs, binding to and activating TLR-4, subsequently activating downstream NF-κB and other essential molecules, leading to the release of multiple factors associated with tumor proliferation and invasion, creating a microenvironment conducive to local recurrence and metastasis, and promoting tumor progression and drug resistance. This review assessed studies on the resistance of several tumor cells to commonly utilized anticancer treatments induced by TLR-4 to better comprehend the phenomena and mechanism of TLR-4-dependent resistance, as well as to put forward suggestions and insights for overcoming tumor resistance.

30 September 2020 in Life Sciences
Verified
Journal Article
Closed access
DMDi Ma
Di Ma
JHJie Hu
Jie Hu
WXWenqi Xu
Wenqi Xu
YWYan Wang
Yan Wang
JWJuan Wang
Juan Wang
LLLi Liu
Li Liu


1 April 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YLYuhua Li
Yuhua Li
YSYang Sun
Yang Sun
QZQian Zhang
Qian Zhang
YLYongsheng Liu
Yongsheng Liu
YNYinbo Niu
Yinbo Niu
DCDe Cai
De Cai

11 July 2026 in BMC Neurology
Verified
Journal Article
Open access
PDF file
DCDachuan Chang
Dachuan Chang
XBXufang Bao
Xufang Bao
YLYuhua Li
Yuhua Li
Anti-myelin-associated glycoprotein (MAG) neuropathy is an uncommon IgM-mediated autoimmune demyelinating peripheral neuropathy, which is prone to misdiagn

22 September 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RCRui Chen
Rui Chen
DXDeduo Xu
Deduo Xu
YLYuhua Li
Yuhua Li
JYJun Yang
Jun Yang
Chronic low back pain secondary to intervertebral disc degeneration (IVDD) is the leading cause of disability across all musculoskeletal disorders worldwide. For decades, gut-disc crosstalk research has been framed almost exclusively by a systemic inflammatory paradigm, in which circulating pro-inflammatory cytokines (e.g., TNF-α, IL-1β) act as obligate mediators linking gut microbial dysbiosis to intervertebral disc degeneration. However, multi-cohort two-sample Mendelian randomization (MR) analyses have not identified significant mediation by the circulating inflammatory factors tested to date, exposing a gap in current mechanistic frameworks. A null indirect effect indicates that the measured mediators did not statistically explain the exposure-outcome association; it does not exclude a contribution from untested systemic pathways. Two core protective commensal taxa, Akkermansia muciniphila (Akk) and Eubacterium coprostanoligenes , have been genetically validated to reduce IVDD risk, yet their beneficial effects cannot be explained by systemic immune activation. Focusing on mucosal immunology and tissue-localized immune homeostasis, this review integrates human genetic data, in vitro nucleus pulposus experiments, in vivo bacterial extracellular vesicle (EV) evidence, and clinical endplate microbiome profiles to delineate three candidate gut mucosa-derived immune regulatory axes that are not explained by the circulating cytokines measured to date: (1) microbe-derived soluble metabolites—which are themselves circulating mediators—reshape local disc metabolic and immune responses via epigenetic modulation and receptor signaling; (2) EVs secreted by A. muciniphila act as cross-barrier immune messengers targeting the avascular disc tissue; (3) gut bacterial fragments translocate across damaged endplate barriers to trigger site-specific immune remodeling without elevating systemic inflammatory markers. This three-pathway framework offers one possible reconciliation of the null mediation findings from MR studies with the collapse of intrinsic disc immune privilege. Each proposed axis remains incompletely validated, and the available evidence does not establish that they operate independently of untested systemic immune pathways. We further summarize methodological limitations of gut-spine microbiome research and outline mucosa-targeted microbial immunotherapies for chronic low back pain. Collectively, this framework helps shift the field away from over-reliance on systemic inflammation as the sole mechanistic explanation for IVDD pathogenesis.